Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo (GB)
|ClinicalTrials.gov Identifier: NCT01006421|
Recruitment Status : Unknown
Verified November 2009 by King Saud University.
Recruitment status was: Recruiting
First Posted : November 2, 2009
Last Update Posted : November 5, 2009
Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available.
Phototherapy is among the successful treatments but gives modest results. Some reports documented the usefulness of Ginkgo Biloba (GB) when used alone in Vitiligo treatment.
|Condition or disease||Intervention/treatment|
|Vitiligo||Dietary Supplement: GINGKO BILOBA|
Adding GB to phototherapy, especially the most commonly used one; Narrow-Band UVB (NBUVB) might give better results than using either one alone. This might improve repigmentation as well as patients' quality-of-life. (QOL).
This will be a prospective double-blind randomized controlled clinical trial. One-hundred-sixty Vitiligo patients will be randomly divided into 2 groups( 80 patients per group).
One group will receive oral GB (2 tablets of 60 mgs twice daily) with NBUVB twice weekly.
The other group will receive placebo tablets( identical in size, shape and color) to GB twice daily with NBUVB twice weekly.
Both groups will be treated for 6 months. Standard protocol of phototherapy will be used for both groups.
Our aim here is to see whether adding GB to NBUVB will lead to better repigmentation than placebo or not.
|Study Type :||Observational|
|Estimated Enrollment :||160 participants|
|Observational Model:||Case Control|
|Official Title:||Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo : A Randomized Double - Blind Placebo Controlled Trial|
|Study Start Date :||January 2009|
|Estimated Study Completion Date :||January 2011|
Dietary Supplement: GINGKO BILOBA
- Repigmentation (more than 50% from baseline) as the primary outcome [ Time Frame: 3,6 and 9 months ]
- Quality-of-life - as secondary outcome . [ Time Frame: 3,6 and 9 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01006421
|Contact: KHALID M ALGHAMDI, MDfirstname.lastname@example.org|
|King Khalid University Hospital||Recruiting|
|Riyadh, Central, Saudi Arabia|
|Contact: KHALID M ALGHAMDI, MD 4690815 email@example.com|
|Principal Investigator: KHALID M ALGHAMDI, MD|
|Study Chair:||KHALID M ALGHAMDI, MD||KSU|